FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

For research purposes only. Full disclaimer →

Protocols
8

My Mounjaro Protocol — 8 Weeks In

Ash Hamilton·6 months ago
I have been running Mounjaro for about 8 weeks now and wanted to share my full protocol with the community. After spending a few weeks researching dosages and reading through published literature, I settled on what I think is a solid approach. I started conservatively and titrated up over the first two weeks. Administration is subcutaneous, rotating injection sites between the abdomen and upper thigh. I dose in the morning on an empty stomach and wait at least 30 minutes before eating. The first couple weeks were uneventful, which I expected. Around week 3-4 I started noticing subtle changes. By week 6, the effects were more pronounced. Sleep quality improved noticeably, which was an unexpected but welcome benefit. I keep a daily log tracking subjective wellbeing, sleep quality, and any side effects. So far the only side effect has been mild injection site redness that resolves within an hour. I plan to continue for another 4 weeks and then assess whether to extend. Happy to answer any questions about my experience so far.

Comments (9)

Kai HardyDEMO·6 months ago

Great write-up. I have been running a similar Mounjaro protocol and my experience aligns pretty closely with what you described. The sleep improvements were the first thing I noticed too, usually around week 2-3. One thing I would add is that I found keeping injection sites consistent with rotation between 4-5 spots worked better than random placement. Less irritation overall.

4
Bailey ButlerDEMO·6 months ago

This matches my experience with Mounjaro almost exactly. The timeline you describe — subtle at first, then clearly noticeable by week 4-5 — is very typical from what I have seen across multiple reports. For anyone reading this and feeling impatient in the first couple weeks, stick with it. The effects are cumulative and take time to establish.

5
Dallas ChambersDEMO·6 months ago

Appreciate the honest assessment. Too many Mounjaro reviews read like advertisements. The moderate but meaningful improvement you describe is exactly what I experienced as well. I think the community benefits more from realistic reports like this than from overhyped claims.

6
Dex HunterDEMO·6 months ago

Question for you: did you get bloodwork done before and during your Mounjaro protocol? I am about to start and trying to decide which panels to run. Obviously the basics but curious if there are any specific markers that are particularly informative for tracking Mounjaro response.

2
Zev BrennanDEMO·6 months ago

I ran Mounjaro at a slightly higher dose than what you used and found the results were actually about the same. This lines up with the dose-response data suggesting there is a ceiling effect. Higher dose just meant more injection site irritation without additional benefit. Your approach seems well-calibrated.

3
Sam BakerDEMO·6 months ago

The conservative start and titration approach is the way to go. I have seen too many people jump to full dose immediately and get discouraged by side effects that would not have happened with gradual introduction. Your patience is paying off.

0
Jesse AshfordDEMO·6 months ago

Morning dosing on an empty stomach with 30-minute wait - is that based on specific pharmacokinetic data or personal preference? I have been dosing in the evening before bed and wondering if timing matters for bioavailability.

0
Blake AshfordDEMO·6 months ago

The daily log tracking is the part most people skip and it is the most valuable part. After my first cycle I wished I had tracked more consistently. Second cycle I used a simple spreadsheet and it made evaluating the protocol so much easier.

0
Harper AllenDEMO·6 months ago

Injection site redness that resolves within an hour is totally normal and nothing to worry about. Some people panic about it but mild local reactions are expected with SubQ peptide administration. As long as it is not spreading or lasting longer you are fine.

0

Sign in to comment.